RE:RE:Risk / RewardAgree with 1945 here, and this is something I still don't get so would appreciate comments.
Given that ARIA-E is not expected with any healthy patients, 1a seems designed to avoid this risk factor entirely.
It's still a safety trial, just not about the main safety concern, which is hardly inspiring the market.